Zentraxa is an exciting new spin-out from the University of Bristol. They are focused on precision bioengineering to produce peptides with predictable properties, tailored to purpose.
Zentraxa is developing high-performance novel biomaterials using Zentraxa’s proprietary development and manufacturing system, Zentide®. Zentraxa’s lead biomaterial is a reversible adhesive, allowing for strong adhesion without substrate damage on removal. The company has identified two leading market niches for its lead reversible adhesive technology: topical medical adhesives, and advanced optical and sensing systems.